TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.
News  ›  GlobeNewswire Inc.

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Na
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

BioAtla and GATC Health announced a $40 million special purpose vehicle transaction to advance ozuriftamab vedotin (Oz-V) into a Phase 3 registrational trial for 2L+ oropharyngeal squamous cell carcinoma. BioAtla will receive an initial $5 million with the remaining $35 million expected in Q1 2026, retaining 65% ownership of Oz-V while Inversagen AI, LLC receives 35%. The Phase 3 trial is anticipated to begin enrollment in early 2026 with potential for accelerated approval.

Insights
BCAB   positive

BioAtla secured $40 million in funding to advance its lead candidate Oz-V into Phase 3 development with a clear regulatory pathway for potential accelerated approval. The company retains 65% ownership, maintains control of trial execution, and is exploring expansion into additional HPV-positive cancer indications, representing significant value creation and de-risking of development.

Keywords
#ozuriftamab vedotin #Phase 3 trial #oropharyngeal squamous cell carcinoma #special purpose vehicle #ROR2 targeting #accelerated approval #senolytic therapy #HPV-positive cancers

Tickers
BCAB
← Prev: Down But Not Out: 5 AI Laggards From 2025 That Could Explode In 2026